No more carb counting, no more insulin dose calculations, no more walking the tightrope between hypos and highs? This is, indeed, the holy grail promise of “smart insulin,” or glucose-responsive insulin, the focus of a recent joint investment from JDRF and Sanofi. The $4.6 million in funding...